FDA panel again rejects wider use of J&J's Xarelto

January 16, 2014

A panel of Food and Drug Administration experts again opposed expanding use of Johnson & Johnson's blood thinner Xarelto to reduce dangerous blood clots in a new group of patients, those with acute coronary artery disease.

The FDA panel on Thursday voted unanimously against broader use of the pill, saying too much information is missing from company studies to accurately gauge Xarelto's benefit. The same panel also voted against broader approval in 2012.

The FDA, which is not required to follow the panel's advice, has also twice rejected J&J's request to approve Xarelto for preventing life-threatening blood clots in patients with acute .

J&J already markets the pill for several patient groups, including those with an irregular heartbeat and those undergoing hip or knee replacement surgery.

Explore further: Bayer drug unproven as stroke preventer: US

Related Stories

Bayer drug unproven as stroke preventer: US

September 6, 2011

US regulators said Tuesday that Xarelto, a Bayer-made drug approved in July for preventing blood clots, is so far unproven for a new proposed use as a stroke preventer.

J&J again seeks more approvals for clot blocker

September 7, 2012

(AP)—Johnson & Johnson has given the Food and Drug Administration additional data to on its new anticlotting drug, in a second attempt to get approval for more uses.

Xarelto's approval expanded

November 5, 2012

(HealthDay)—Approval of the anti-clotting drug Xarelto (rivaroxaban) has been expanded by the U.S. Food and Drug Administration to include treating deep vein thrombosis (DVT) or pulmonary embolism.

FDA advisers unanimously back J&J hepatitis C drug

October 24, 2013

An experimental hepatitis C drug from Johnson & Johnson has won unanimous support from government experts who say the medication should be approved to treat patients infected with the liver-destroying virus.

Experimental diabetes drug makes comeback

December 12, 2013

A panel of federal health advisers has backed the benefits of an experimental diabetes drug that uses a new method to reduce blood sugar, setting aside previous concerns about the pill's safety.

Recommended for you

Re-framing the placebo effect and informed consent

October 29, 2015

(Medical Xpress)—Imagine that your doctor knows from evidence-based studies that if he tells you about certain, small side-effects to a particular drug, you are significantly more likely to experience that side effect than ...

Can exercise be replaced with a pill?

October 2, 2015

Everyone knows that exercise improves health, and ongoing research continues to uncover increasingly detailed information on its benefits for metabolism, circulation, and improved functioning of organs such as the heart, ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.